YD Bio (YDESW) Common Equity (2024 - 2026)

YD Bio (YDESW) has reported Common Equity for 3 consecutive years, with $4.5 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Common Equity fell 12.07% year-over-year to $4.5 million in Q2 2026; TTM through Jun 2026 was $4.5 million, a 12.07% decrease from a year earlier, with the FY2025 full-year figure at -$2.9 million, down 143.33% from the prior year.
• Common Equity was $4.5 million for Q2 2026 at YD Bio, up from -$2.9 million in the prior quarter.
• Over five years, Common Equity peaked at $6.6 million in Q4 2024 and troughed at -$2.9 million in Q4 2025.
• A 3-year average of $3.3 million and a median of $4.8 million in 2025 frame the typical range for Common Equity.
• Across the five-year window, Common Equity plunged 143.33% in 2025 and declined 12.07% in 2026, its largest moves.
• Over 3 years, Common Equity stood at $6.6 million in 2024, then sank by 143.33% to -$2.9 million in 2025, then jumped by 256.67% to $4.5 million in 2026.
• The last three Common Equity figures came in at $4.5 million (Q2 2026), -$2.9 million (Q4 2025), and $5.1 million (Q2 2025), per Business Quant data.